Jennifer Fisher, MMSc, PA-C

Although bimekizumab carries a precaution for suicidal ideation and behavior, current data suggest it may improve mental health outcomes for patients with psoriasis.

Upadacitinib’s targeted inhibition of JAK1 offers a novel strategy for managing bullous pemphigoid and, in rare, treatment-resistant cases, may induce sustained remission following immune modulation.

Abrocitinib’s targeted inhibition of JAK1 offers effective control of AD, but may, in rare instances, lead to a shift in immune expression resulting in paradoxical psoriasis.

Explore the potential of GLP-1 receptor agonists in psoriasis management, highlighting their immunomodulatory effects and metabolic benefits for patients.

CD19 CAR T-cell therapy may modulate immune dysregulation in underlying diseases such as psoriasis.